Biology-inspired synthesis of compound libraries

Abstract.Biologically active small molecules represent the basis for chemical biology applications in which small molecules are used as chemical tools to probe biological processes. In this report, we review two approaches to design and synthesize compound libraries for biological screenings, i.e., diversity-oriented synthesis (DOS) and biology-oriented synthesis (BIOS).

[1]  Derek S. Tan,et al.  Advancing chemistry and biology through diversity-oriented synthesis of natural product-like libraries. , 2005, Current opinion in chemical biology.

[2]  E. LaVoie,et al.  Bioisosterism: A Rational Approach in Drug Design , 1997 .

[3]  V. Motilva,et al.  New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists , 2004 .

[4]  E. Fauman,et al.  Crystal Structure of the Catalytic Domain of the Human Cell Cycle Control Phosphatase, Cdc25A , 1998, Cell.

[5]  I. Arkin,et al.  Monte Carlo estimation of the number of possible protein folds: Effects of sampling bias and folds distributions , 2003, Proteins.

[6]  C. Dobson.  Chemical space and biology , 2004, Nature.

[7]  H. Waldmann,et al.  Synthesis of the protein phosphatase 2A inhibitor (4S,5S,6S,10S,11S,12S)-cytostatin. , 2002, Angewandte Chemie.

[8]  V. Jordan,et al.  Selective estrogen receptor modulation: concept and consequences in cancer. , 2004, Cancer cell.

[9]  P. Wipf,et al.  Dual-specificity phosphatases as targets for antineoplastic agents , 2002, Nature Reviews Drug Discovery.

[10]  S. Schreiber,et al.  Diversity‐Oriented Synthesis of Biaryl‐Containing Medium Rings Using a One Bead/One Stock Solution Platform. , 2002 .

[11]  Ronald J Quinn,et al.  A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets. , 2006, Journal of natural products.

[12]  Jeffrey Augen,et al.  The evolving role of information technology in the drug discovery process. , 2002, Drug discovery today.

[13]  H. Waldmann,et al.  Total synthesis and biological evaluation of the protein phosphatase 2A inhibitor cytostatin and analogues. , 2004, Chemistry.

[14]  H. Waldmann,et al.  Stereocomplementary synthesis of a natural product-derived compound collection on a solid phase. , 2006, Chemical communications.

[15]  Tim J. P. Hubbard,et al.  SCOP database in 2004: refinements integrate structure and sequence family data , 2004, Nucleic Acids Res..

[16]  Herbert Waldmann,et al.  Asymmetric solid-phase synthesis of 6,6-spiroketals. , 2004, Angewandte Chemie.

[17]  J. Boutin,et al.  Peroxisome Proliferator-activated Receptor γ (PPARγ) as a Molecular Target for the Soy Phytoestrogen Genistein* , 2003, The Journal of Biological Chemistry.

[18]  Ian J. Deary,et al.  11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics , 2004 .

[19]  Robert B Russell,et al.  Finding functional sites in structural genomics proteins. , 2004, Structure.

[20]  H. Waldmann,et al.  Synthesis and biological evaluation of an indomethacin library reveals a new class of angiogenesis-related kinase inhibitors. , 2004, Angewandte Chemie.

[21]  Stuart L. Schreiber,et al.  Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays , 2002, Nature.

[22]  W. Patrick Walters,et al.  A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.

[23]  H. Waldmann,et al.  Biology-oriented synthesis of stereochemically diverse natural-product-derived compound collections by iterative allylations on a solid support. , 2007, Chemistry.

[24]  R. Evans,et al.  Discovery and Optimization of Non‐steroidal FXR Agonists from Natural Product‐Like Libraries. , 2003 .

[25]  Stefan Wetzel,et al.  Natural Product Scaffolds and Protein Structure Similarity Clustering (PSSC) as Inspiration Sources for Compound Library Design in Chemogenomics and Drug Development , 2006 .

[26]  S. Haggarty,et al.  High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. , 1999, Chemistry & biology.

[27]  Herbert Waldmann,et al.  Traceless Fischer indole synthesis on the solid phase. , 2003, Chemical communications.

[28]  John Maynard Smith,et al.  Natural Selection and the Concept of a Protein Space , 1970, Nature.

[29]  M. Kelly-Borges,et al.  Dysidiolide: A Novel Protein Phosphatase Inhibitor from the Caribbean Sponge Dysidea etheria de Laubenfels , 1996 .

[30]  H. Waldmann,et al.  Solid phase synthesis of a spiro[5.5]ketal library. , 2005, Chemical communications.

[31]  Stuart L Schreiber,et al.  Skeletal diversity via a branched pathway: efficient synthesis of 29 400 discrete, polycyclic compounds and their arraying into stock solutions. , 2002, Journal of the American Chemical Society.

[32]  David R Spring,et al.  Diversity-oriented synthesis; a challenge for synthetic chemists. , 2003, Organic & biomolecular chemistry.

[33]  Herbert Waldmann,et al.  Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  I. Deary,et al.  11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Kapoor,et al.  HR22C16: a potent small-molecule probe for the dynamics of cell division. , 2003, Angewandte Chemie.

[36]  Herbert Waldmann,et al.  Natural product-derived modulators of cell cycle progression and viral entry by enantioselective oxa Diels-Alder reactions on the solid phase. , 2007, Chemistry & biology.

[37]  Herbert Waldmann,et al.  Protein Structure Similarity as Guiding Principle for Combinatorial Library Design , 2003, Biological chemistry.

[38]  Stefan Wetzel,et al.  The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..

[39]  Burkhard Rost,et al.  Domains, motifs and clusters in the protein universe. , 2003, Current opinion in chemical biology.

[40]  E. Gulve,et al.  Chemistry and biochemistry of type 2 diabetes. , 2004, Chemical reviews.

[41]  H. Waldmann,et al.  Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors. , 2002, Angewandte Chemie.

[42]  Herbert Waldmann,et al.  Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. , 2005, Drug discovery today.

[43]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[44]  C. Chothia,et al.  Evolution of the Protein Repertoire , 2003, Science.

[45]  Paul A Clemons,et al.  Relationship of stereochemical and skeletal diversity of small molecules to cellular measurement space. , 2004, Journal of the American Chemical Society.

[46]  P. Furet,et al.  Total synthesis and biological evaluation of the nakijiquinones. , 2001, Journal of the American Chemical Society.

[47]  T. Kirchhausen,et al.  Synthesis of a 10,000-membered library of molecules resembling carpanone and discovery of vesicular traffic inhibitors. , 2006, Journal of the American Chemical Society.

[48]  G. Chrousos.  Is 11beta-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Herbert Waldmann,et al.  Design of compound libraries based on natural product scaffolds and protein structure similarity clustering (PSSC). , 2005, Molecular bioSystems.

[50]  Stefan Wetzel,et al.  Protein structure similarity clustering: dynamic treatment of PDB structures facilitates clustering. , 2006, Angewandte Chemie.

[51]  M J Sternberg,et al.  Supersites within superfolds. Binding site similarity in the absence of homology. , 1998, Journal of molecular biology.

[52]  L. V. Van Gaal,et al.  Are all glitazones the same? , 2002, Diabetes/metabolism research and reviews.

[53]  A. Schuffenhauer,et al.  Charting biologically relevant chemical space: a structural classification of natural products (SCONP). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  S. Schreiber,et al.  A Strategy for Macrocyclic Ring Closure and Functionalization Aimed toward Split-Pool Syntheses , 1999 .

[55]  H. Waldmann,et al.  Stereoselective allylation of aldehydes on solid support and its application in biology-oriented synthesis (BIOS) , 2007 .

[56]  H. Waldmann,et al.  Natural products are biologically validated starting points in structural space for compound library development: solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. , 2002, Angewandte Chemie.

[57]  Stuart L Schreiber,et al.  Generating Diverse Skeletons of Small Molecules Combinatorially , 2003, Science.

[58]  Ronald J Quinn,et al.  Identification of Protein Fold Topology Shared between Different Folds Inhibited by Natural Products , 2007, Chembiochem : a European journal of chemical biology.

[59]  S. Haggarty,et al.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.

[60]  E. Koonin,et al.  The structure of the protein universe and genome evolution , 2002, Nature.

[61]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[62]  Harald Schwalbe,et al.  Identification of inhibitors for mycobacterial protein tyrosine phosphatase B (MptpB) by biology-oriented synthesis (BIOS). , 2007, Chemistry, an Asian journal.

[63]  Herbert Waldmann,et al.  Protein structure similarity clustering (PSSC) and natural product structure as inspiration sources for drug development and chemical genomics. , 2005, Current opinion in chemical biology.

[64]  E. Koonin,et al.  Emergence of diverse biochemical activities in evolutionarily conserved structural scaffolds of proteins. , 2003, Current opinion in chemical biology.

[65]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[66]  J. Thornton,et al.  Searching for functional sites in protein structures. , 2004, Current opinion in chemical biology.

[67]  C. Lanni,et al.  Acetylcholinesterase inhibitors: novel activities of old molecules. , 2004, Pharmacological research.

[68]  Stuart L Schreiber,et al.  A planning strategy for diversity-oriented synthesis. , 2004, Angewandte Chemie.

[69]  R. Evans,et al.  Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. , 2003, Organic & biomolecular chemistry.

[70]  J. Holbrook,et al.  Opportunities and Limits in Creating New Enzymes , 1992 .

[71]  H. Waldmann,et al.  Solid phase synthesis of highly substituted tetrahydropyrans by tandem ene-reaction/intramolecular Sakurai cyclization. , 2007, Journal of combinatorial chemistry.

[72]  H. Waldmann,et al.  Solid-phase synthesis of dysidiolide-derived protein phosphatase inhibitors. , 2002, Journal of the American Chemical Society.

[73]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.

[74]  B. Walker,et al.  11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease , 2003, Expert opinion on therapeutic targets.

[75]  H. Waldmann,et al.  Natural Product-derived Compound Libraries and Protein Structure Similarity as Guiding Principles for the Discovery of Drug Candidates , 2004 .

[76]  V. Laudet,et al.  The nuclear receptor superfamily , 2003, Journal of Cell Science.

[77]  S. Schreiber,et al.  Pairwise use of complexity-generating reactions in diversity-oriented organic synthesis. , 2000, Organic letters.

[78]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[79]  Harren Jhoti,et al.  High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.

[80]  David A. Lee,et al.  Progress towards mapping the universe of protein folds , 2004, Genome Biology.

[81]  M. Bowman,et al.  A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. , 2003, Molecular cell.

[82]  H. Waldmann,et al.  Enantioselective Catalysis on the Solid Phase: Synthesis of Natural Product‐Derived Tetrahydropyrans Employing the Enantioselective Oxa‐Diels–Alder Reaction , 2006 .

[83]  Stuart L Schreiber,et al.  A synthesis strategy yielding skeletally diverse small molecules combinatorially. , 2004, Journal of the American Chemical Society.

[84]  Herbert Waldmann,et al.  Compound library development guided by protein structure similarity clustering and natural product structure. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Daniel W. A. Buchan,et al.  A structural perspective on genome evolution. , 2003 .

[86]  John Moult,et al.  A unifold, mesofold, and superfold model of protein fold use , 2002, Proteins.

[87]  V. Motilva,et al.  New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists. , 2004, Current pharmaceutical design.

[88]  H. Waldmann,et al.  Solid-Phase Synthesis and Biological Evaluation of a Teleocidin Library—Discovery of a Selective PKCδ Down Regulator , 2000 .

[89]  A G Murzin,et al.  SCOP: a structural classification of proteins database for the investigation of sequences and structures. , 1995, Journal of molecular biology.

[90]  Herbert Waldmann,et al.  Natural Product-Guided Synthesis of a Spiroacetal Collection Reveals Modulators of Tubulin Cytoskeleton Integrity , 2005 .

[91]  Herbert Waldmann,et al.  Inhibitors of Protein Tyrosine Phosphatases: Next‐Generation Drugs? , 2005 .